ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will shell out $50 million for global access to Merck & Co.’s MK-1775, a WEE1 kinase inhibitor in Phase IIa studies for the treatment of ovarian cancer. Preclinical studies suggest MK-1775, which blocks a protein involved in the regulation of the cell-division cycle, could enhance the efficacy of chemotherapies that work by damaging tumor DNA. The deal expands AstraZeneca’s ovarian cancer development pipeline, which includes olaparib. Olaparib blocks PARP, an enzyme involved in DNA repair. Earlier this month, the drug entered Phase III studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X